Skip to main content
    U

    UroGen Pharma Ltd (URGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $28.10
    +1.92 (+7.33%)

    Market Cap: $1.28B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    UroGen Pharma Ltd (URGN) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2026. Financial statements from company filings, amounts in US dollars.

    UroGen Pharma reported revenue of $109.79M for the fiscal year ended Dec 31, 2025, up 21.4% from the year before. That year, net income was -$153.49M with a net margin of -139.8%, operating cash flow was -$162.44M and free cash flow was -$162.73M. The quarter ended Sep 30, 2026 had revenue of $89.00M and net income of -$1.46M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue grew from $17.53M, a compound annual rate of 22.6%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$109.79M+21.4%88.7%-113.7%-139.8%
    Dec 2024$90.40M+9.3%90.2%-107.1%-140.4%
    Dec 2023$82.71M+28.5%88.7%-79.2%-123.6%
    Dec 2022$64.36M+34.0%88.1%-122.8%-170.6%
    Dec 2021$48.04M+307.2%89.3%-192.1%-230.7%
    Dec 2020$11.80M+65450.0%91.4%-1074.2%-1088.9%
    Dec 2019$18.00K-98.4%100.0%-608211.1%-584144.4%
    Dec 2018$1.13M-86.2%-59.8%-6842.2%-6707.2%
    Dec 2017$8.16M-53.5%92.6%-244.5%-245.2%
    Dec 2016$17.53MN/A99.8%4.6%-11.1%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$109.79M$90.40M$82.71M$64.36M$48.04M$11.80M$18.00K$1.13M$8.16M$17.53M
    Cost of revenue$12.45M$8.88M$9.36M$7.65M$5.16M$1.01M$0$1.80M$600.00K$28.00K
    Gross profit$97.34M$81.52M$73.35M$56.70M$42.88M$10.79M$18.00K-$675.00K$7.56M$17.50M
    Research and development$67.11M$57.15M$45.61M$52.91M$47.64M$47.31M$49.30M$36.93M$18.70M$10.29M
    Operating income-$124.86M-$96.78M-$65.54M-$79.04M-$92.29M-$126.74M-$109.48M-$77.18M-$19.95M$798.00K
    Net income-$153.49M-$126.87M-$102.24M-$109.78M-$110.82M-$128.48M-$105.15M-$75.66M-$20.00M-$1.94M
    EBITDAN/AN/AN/AN/AN/A-$125.88M-$108.73M-$76.76M-$19.74MN/A
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$89.00M$72.46M$50.96M$37.84M$27.48M$24.21M$20.25M$24.57M$25.20M$21.85M$18.78M$23.53M
    Gross profit$81.50M$65.88M$46.82M$34.55M$24.20M$20.66M$17.92M$22.09M$22.75M$19.62M$17.05M$21.24M
    Operating income$8.33M$111.00K-$20.26M-$19.11M-$27.39M-$41.45M-$36.91M-$27.66M-$17.55M-$25.84M-$25.74M-$14.61M
    Net income-$1.46M-$14.35M-$23.57M-$26.36M-$33.35M-$49.94M-$43.84M-$37.51M-$23.67M-$33.40M-$32.29M-$26.02M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, long-term debt of $122.21M exceeded cash and equivalents by $11.46M. Shareholder equity was negative, at -$105.47M, as total liabilities of $305.93M exceeded total assets of $200.46M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$200.46M$285.71M$178.31M$135.62M$119.75M$122.00M$202.39M$103.56M$75.55M$23.06M
    Current assets$186.02M$276.13M$169.19M$128.91M$114.39M$115.62M$148.63M$102.24M$74.47M$22.04M
    Cash and equivalents$110.75M$171.99M$95.00M$55.41M$44.36M$52.86M$49.69M$101.32M$37.00M$21.36M
    Total liabilities$305.93M$294.51M$243.52M$224.98M$111.33M$25.65M$22.09M$13.46M$7.04M$6.75M
    Short-term debtN/A$1.53M$819.00K$941.00K$3.33M$1.86MN/AN/AN/AN/A
    Long-term debt$122.21M$121.73M$98.55M$97.54M$0N/AN/AN/AN/A$3.61M
    Shareholder equity-$105.47M-$8.80M-$65.21M-$89.36M$8.41M$96.36M$180.30M$90.09M$68.52M$16.31M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$271.87M$252.59M$253.69M$200.46M$185.05M$208.72M$247.62M$285.71M$301.94M$281.85M$200.57M$178.31M
    Total liabilities$397.09M$384.99M$377.94M$305.93M$300.45M$302.09M$294.08M$294.51M$276.43M$251.53M$240.71M$243.52M
    Cash and equivalents$85.56M$79.13M$109.97M$110.75M$90.04M$92.90M$104.03M$171.99M$124.92M$219.97M$131.44M$95.82M
    Shareholder equity-$125.22M-$132.40M-$124.25M-$105.47M-$115.41M-$93.38M-$46.46M-$8.80M$25.52M$30.31M-$40.13M-$65.21M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$162.44M-$96.77M-$76.38M-$87.56M-$84.89M-$105.89M-$71.02M-$37.33M-$9.57M$4.19M
    Capital expenditures$289.00K$295.00K$194.00K$254.00K$752.00K$1.22M$325.00K$560.00K$271.00K$695.00K
    Free cash flow-$162.73M-$97.06M-$76.57M-$87.81M-$85.64M-$107.10M-$71.34M-$37.89M-$9.84M$3.49M
    Share repurchasesN/AN/AN/A$160.00K$144.00K$66.00KN/A$0$0$579.00K
    Investing cash flow$61.56M-$20.61M-$953.00K$1.06M$4.07M$93.24M-$145.59M$35.29M-$36.28M-$719.00K
    Financing cash flow$39.92M$194.62M$116.93M$97.13M$72.32M$16.53M$165.25M$66.42M$61.59M-$9.00K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$15.20M-$33.01M-$45.32M-$38.33M-$42.27M-$39.83M-$42.02M-$13.62M-$27.66M-$23.75M-$31.73M-$13.00M
    Capital expenditures$72.00K$60.00K$54.00K$17.00K$87.00K$141.00K$44.00K$115.00K$96.00K$84.00K$0$56.00K
    Free cash flow-$15.27M-$33.07M-$45.37M-$38.34M-$42.36M-$39.97M-$42.07M-$13.73M-$27.76M-$23.83M-$31.73M-$13.05M
    Last 12 quarters

    Frequently Asked Questions About URGN

    What is UroGen Pharma's annual revenue?

    UroGen Pharma reported revenue of $109.79M for the fiscal year ended Dec 31, 2025.

    How fast is UroGen Pharma's revenue growing?

    Revenue was up 21.4% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 19.5%.

    Is UroGen Pharma profitable?

    No. UroGen Pharma reported net income of -$153.49M for the fiscal year ended Dec 31, 2025, with a net margin of -139.8%.

    How much free cash flow does URGN generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$162.44M minus capital expenditures of $289.00K produced free cash flow of -$162.73M.

    How much debt does UroGen Pharma have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $122.21M and cash and equivalents of $110.75M.